Pneumonia, Viral Clinical Trial
Official title:
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study
Low radiation doses produce anti-inflammatory effects, which may be useful in the treatment of respiratory complications of COVID-19. This type of treatment is non-invasive and therefore, a priori, it can be used in all types of patients. Main objective: To evaluate the efficacy of low-dose lung irradiation as an adjunctive treatment in interstitial pneumonia in patients with COVID-19 by improving the PAFI O2 by 20% measured 48h after treatment with respect to the pre baseline measurement. -irradiation.
Study design: This is a prospective multicenter study in 2 phases: 1. Exploratory phase. It will include 10 patients, to assess the feasibility and efficacy of low-dose lung irradiation. If a minimum efficiency of 30% is not achieved, the study will not be continued. 2. Comparative phase in two groups, a control group, which will only receive pharmacological treatment, and an experimental one. It will include 96 patients, the allocation will be 1: 2, that is, 32 in the control arm and 64 in the experimental arm, which will receive low-dose lung irradiation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04517123 -
Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study
|
N/A | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Completed |
NCT01271842 -
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
|
N/A | |
| Completed |
NCT04724538 -
Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04414293 -
Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis
|
N/A | |
| Completed |
NCT04047719 -
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
|
||
| Recruiting |
NCT04528888 -
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
|
Phase 3 | |
| Completed |
NCT04606407 -
Inhaled NO for the Treatment of Viral Pneumonia in Adults
|
N/A | |
| Terminated |
NCT04619693 -
Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
|
||
| Recruiting |
NCT05077917 -
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
|
Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT05976581 -
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
|
N/A | |
| Active, not recruiting |
NCT04381364 -
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
|
Phase 2 | |
| Completed |
NCT04422613 -
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
|
N/A | |
| Completed |
NCT04479540 -
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease
|
N/A | |
| Recruiting |
NCT04474340 -
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
|
Phase 1 | |
| Completed |
NCT04424836 -
HFNC Treatment in COVID-19 Pneumonia
|
||
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04387799 -
Determinants of COVID-19 Pneumonia (MC-19)
|
||
| Completed |
NCT04382547 -
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
|
Phase 1/Phase 2 |